Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 3,847 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $23.38, for a total value of $89,942.86. Following the completion of the transaction, the insider owned 121,338 shares in the company, valued at approximately $2,836,882.44. This represents a 3.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gwenn Hansen also recently made the following trade(s):

• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $107,880.00.

Nurix Therapeutics Trading Down 0.1%

NRIX stock opened at $23.58 on Friday. The firm has a 50-day moving average price of $20.43 and a 200-day moving average price of $17.81. Nurix Therapeutics, Inc. has a 12 month low of $8.19 and a 12 month high of $25.08. The stock has a market capitalization of $2.45 billion, a P/E ratio of -6.83 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The company had revenue of $9.04 million for the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. As a group, equities analysts predict that Nurix Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Institutional Trading of Nurix Therapeutics

Institutional investors have recently modified their holdings of the business. General Atlantic L.P. bought a new position in Nurix Therapeutics during the 4th quarter worth $92,899,000. Morgan Stanley grew its position in shares of Nurix Therapeutics by 115.9% in the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock valued at $92,594,000 after buying an additional 2,620,323 shares during the last quarter. Rubric Capital Management LP bought a new stake in shares of Nurix Therapeutics in the 4th quarter valued at about $46,930,000. Braidwell LP acquired a new stake in shares of Nurix Therapeutics in the fourth quarter valued at about $41,428,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Nurix Therapeutics by 195.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,248,361 shares of the company’s stock valued at $61,622,000 after buying an additional 2,149,268 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. HC Wainwright boosted their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Wells Fargo & Company downgraded Nurix Therapeutics from an “overweight” rating to a “hold” rating and dropped their target price for the company from $28.00 to $25.00 in a research report on Monday, June 8th. Wall Street Zen raised Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Robert W. Baird boosted their price target on Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, Stifel Nicolaus upped their price objective on Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.